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Abstract
Background: We have recently shown that treatment of mice with the neutral endopeptidase (NEP) inhibitor
phosphoramidon (PA) improves the bioavailability and tumor uptake of biodegradable radiopeptides. For the
truncated gastrin radiotracer [111In-DOTA]MG11 ([(DOTA)DGlu10]gastrin(10–17)), this method led to impressively
high tumor-to-kidney ratios. Translation of this concept in the clinic requires the use of certified NEP inhibitors,
such as thiorphan (TO) and its orally administered prodrug racecadotril (Race). Besides NEP, angiotensin-converting
enzyme (ACE) has also been implicated in the catabolism of gastrin analogs. In the present study, we first compared
the effects induced by NEP inhibition (using PA, TO, or Race) and/or by ACE inhibition (using lisinopril, Lis) on the
biodistribution profile of [111In-DOTA]MG11 in mice. In addition, we compared the efficacy of PA and TO at different
administered doses to enhance tumor uptake.
Methods: [111In-DOTA]MG11 was coinjected with (a) vehicle, (b) PA (300 μg), (c) TO (150 μg), (d) Lis (100 μg), (e) PA
(300 μg) plus Lis (100 μg), or (f) 30–40 min after intraperitoneal (ip) injection of Race (3 mg) in SCID mice bearing AR42J
xenografts. In addition, [111In-DOTA]MG11 was coinjected with vehicle, or with progressively increasing amounts of PA
(3, 30, or 300 μg) or TO (1.5, 15, and 150 μg) in SCID mice bearing twin A431-CCK2R(+/−) tumors. In all above cases,
biodistribution was conducted at 4 h postinjection (pi).
Results: During NEP inhibition, the uptake of [111In-DOTA]MG11 in the AR42J tumors impressively increased
from 1.8 ± 1.0 % ID/g (controls) to 15.3 ± 4.7 % ID/g (PA) and 12.3 ± 3.6 % ID/g (TO), while with Race tumor
values reached 6.8 ± 2.8 % ID/g. Conversely, Lis had no effect on tumor uptake and no additive effect when
coinjected with PA. During the dose dependence study in mice, PA turned out to be more efficacious in enhancing
tumor uptake of [111In-DOTA]MG11 in the CCK2R-positive tumors compared to equimolar amounts of TO. In all cases,
renal accumulation remained low, resulting in notable increases of tumor-to-kidney ratios.
Conclusions: This study has confirmed NEP as the predominant degrading enzyme of [111In-DOTA]MG11 and ruled
out the involvement of ACE in the in vivo catabolism of the radiotracer. NEP inhibition with the clinically tested NEP
inhibitors TO and Race resulted in significant enhancement of tumor-to-kidney ratios vs. controls. However, compared
with PA, TO and its prodrug Race induced less potent increases of tumor uptake, highlighting the significance of
inhibitor type, administration route, and dose for implementing a first proof-of-principle study in human.
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Background
Cholecystokinin subtype 2 receptors (CCK2Rs) have
attracted much attention in nuclear oncology due to
their overexpression in various human tumors, including
medullary thyroid carcinoma (MTC), small cell lung
cancer, astrocytomas, and stromal ovarian cancers [1–4].
Accordingly, peptide radioligands based on gastrin or on
cholecystokinin (CCK) have been proposed for diagnos-
tic imaging and radionuclide therapy of CCK2R-positive
tumors [5, 6].
Human gastrin I is a C-terminally amidated heptadeca-
peptide characterized by a penta-Glu repeat in positions 6
through 10 (pGlu-Gly-Pro-Trp-Leu-(Glu)5-Ala-Tyr-Gly-
Trp-Met-Asp-Phe-NH2; Fig. 1) [7]. This highly polar and
negatively charged amino acid sequence determines im-
portant biological properties of gastrin and its radiolabeled
analogs. Thus, Glu6–10-containing radioligands show high
receptor affinity and are metabolically robust. As a result,
they efficiently localize in CCK2R-rich lesions in rodents
and in patients, but their application in the clinic has been
hitherto restricted by their unfavorably high renal reten-
tion. Conversely, truncated desGlu6–10 gastrin analogs, as
for example [111In-DOTA]MG11 ([(DOTA)DGlu10]gas-
trin(10–17); Fig. 1), display favorably low renal uptake but
also severely impaired ability to target CCK2R-positive tu-
mors in vivo, owing to their poor metabolic stability [6, 8].
According to previous reports, proteases that might be
implicated in the degradation of CCK and gastrin analogs
include (a) aminopeptidases [9], (b) angiotensin-converting
enzyme (ACE, EC 3.4.15.1) [10], and (c) neutral endo-
peptidase (NEP, neprilysin, EC 3.4.24.11) [11, 12]. Given
that N-terminal capping is an effective means to pre-
vent peptide degradation by aminopeptidases [9, 13], it
is reasonable to assume that [111In-DOTA]MG11 with
a bulky radiometal chelate attached at the N-terminus
becomes aminopeptidase-resistant. The role of ACE in
the degradation of CCK and different-length gastrin
analogs has been previously investigated in vitro [10].
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Fig. 1 Human gastrin I; [111In-DOTA]MG11; the NEP inhibitors PA, TO, and its prodrug Race; and the ACE inhibitor Lis
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Interestingly, minigastrin (MG, gastrin(5–17)) was
shown to be resistant to ACE, whereas successive
shortening of the penta-Glu chain to truncated gastrin
analogs with less than two Glu residues led to in vitro
degradation by ACE. Accordingly, [111In-DOTA]MG11
is expected to be resistant to ACE by virtue of the polar
111In-DOTA9-DGlu10 sequence, mimicking the Glu9–10
construct of ACE-resistant gastrin(9–17). However, the
role of ACE in the in vivo fate of gastrin analogs,
including [111In-DOTA]MG11, has not been elucidated
yet. The third protease implicated in the metabolism of
gastrin is NEP, an ectoenzyme with broad substrate
specificity and a wide distribution in the body. While
scarcely found in plasma, NEP is abundantly expressed
in most tissues, anchored on the endothelial cell surface
of the vasculature compartment, and in major organs,
such as kidneys, liver, lungs, and the gastrointestinal
tract [14]. The involvement of NEP in the in vitro and
in vivo degradation of gastrin has been well described
in previous reports [11, 12].
We have recently proposed an effective strategy to im-
prove the bioavailability and tumor uptake of biodegrad-
able radiopeptides, involving in situ inhibition of the
degrading protease(s) (e.g., NEP) by coinjection of a
suitable inhibitor (e.g., the NEP inhibitor phosphorami-
don, PA) [15–17]. For the truncated gastrin radiotracer
[111In-DOTA]MG11, this method led to impressive in vivo
stabilization, which translated into remarkably increased
uptake in CCK2R-positive tumors in mice and into high
tumor-to-kidney ratios [15, 18].
The above promising results have prompted further
research toward clinical translation of the proposed
concept in a first “proof-of-principle” study in man,
using [111In-DOTA]MG11 as a paradigm. The success of
this step largely relies on the identification of the
peptidase(s) actually responsible for the proteolytic
degradation of [111In-DOTA]MG11 after its entry in the
circulation by intravenous injection. Rapid in vivo
degradation deteriorates the radiotracer supply to target
sites and eventually compromises its localization on
tumor CCK2R-positive lesions. Therefore, we were first
interested to study the potential involvement of ACE on
the tumor uptake of [111In-DOTA]MG11. For this
purpose, the effect of in situ ACE inhibition by lisinopril
(Lis) [19] alone vs. controls was compared in mice
bearing AR42J tumors. Furthermore, the combination of
dual ACE/NEP inhibition after injection of a Lis and PA
mixture vs. single NEP inhibition by PA was compared
in the same mouse model.
Another important step toward clinical translation is
the assessment of biosafety and efficacy of the NEP
inhibitor intended for human application. It should be
noted that so far, no extensive toxicity studies have been
reported for PA. This bacterial origin and potent NEP
inhibitor has been administered in human only in
homeopathic amounts [16, 20]. Consequently, we
decided to compare the in vivo efficacy of the clinically
certified NEP inhibitor thiorphan (TO) [21, 22] vs. PA to
enhance the tumor uptake of [111In-DOTA]MG11 in the
same mouse model. Racecadotril (Race) is a prodrug of
TO administered orally and a registered antidiarrheal
drug (Fig. 1) [23, 24], which has also been included in
our study. Race was administered intraperitoneally (ip)
due to its poor water solubility prior to [111In-
DOTA]MG11 iv injection.
In the last part of the present study, we have directly
compared the efficacy of TO and PA iv-injected in equi-
molar and progressively increasing doses to enhance the
uptake of [111In-DOTA]MG11 in a double A431-
CCK2R(+/−) tumor mouse model.
Methods
Chemistry and radiochemistry
Chemicals and radionuclides
All chemicals were reagent grade and used without fur-
ther purification. DOTA-MG11 (DOTA-minigastrin 11,
DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) and
DG2 (Demogastrin 2, N4-Gly-DGlu-(Glu)5-Ala-Tyr-
Gly-Trp-Met-Asp-Phe-NH2) [25] were purchased from
PiChem (Graz, Austria). PA (phosphoramidon diso-
dium dehydrate, N-(α-rhamnopyranosyloxyhydroxy-
phosphinyl)-L-leucyl-L-tryptophan × 2Na × 2H2O) was
provided by PeptaNova GmbH (Sandhausen,
Germany). TO (DL-thiorphan, DL-3-mercapto-2-ben-
zylpropanoylglycine) was a kind gift of Prof. B. Roques
(Université René Descartes, Paris, France). Lis (lisino-
pril dehydrate, ((S)1-1-[N2-(1-carboxy-3-phenylpro-
pyl)-lysyl-proline dehydrate, MK 521) and Race
(racecadotril, (RS)-benzyl N-[3-(acetylthio)-2-benzyl-
propanoyl]glycinate) were purchased from Sigma-
Aldrich (Fig. 1).
Indium-111 used for labeling was purchased in the form
of 111InCl3 in a solution of 0.05 M HCl (0.5 mL) from
Mallinckrodt Medical B.V. (Petten, the Netherlands).
Preparation of [111In-DOTA]MG11
Lyophilized DOTA-MG11 was dissolved in water to a
final concentration of 1 mM, and 50 μL aliquots were
stored at −20 °C. Labeling with 111In was conducted in
an Eppendorf vial containing 0.1 M sodium acetate
buffer pH 4.6 in the presence of excess methionine
(Met) to prevent oxidation of Met15 in DOTA-MG11
[26]. Freshly prepared sodium ascorbate buffer
(10 mM) was added in the vial, followed by 111InCl3
solution (37–74 MBq), Met (1000 nmol), and DOTA-
MG11 (10 nmol). The mixture was left to react at
90 °C for 20 min. Prior to performing quality control
by HPLC, EDTA in 0.1 M acetate buffer (pH 4.6) was
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added to a final concentration of 1 mM to the label-
ing reaction mixture as a “free” 111In3+ scavenger.
Quality control of [111In-DOTA]MG11
For quality control of the labeled reaction mixture,
RP-HPLC was performed using system 1: A Waters
Chromatograph (Waters, Vienna, Austria) based on a
600 solvent delivery system coupled to a Waters 996
photodiode array UV detector and a Gabi gamma de-
tector (Raytest, RSM Analytische Instrumente GmbH,
Germany) employing a 20 μL injection loop was applied.
The Millennium Software (Waters, USA) was used for
data processing and chromatographic control, and an
XTerra RP-18 (5 μm, 4.6 mm× 150 mm) cartridge col-
umn (Waters, Germany) was eluted at 1 mL/min flow rate
with a linear gradient starting from 0 % B and advancing
to 40 % B within 40 min (solvent A = 0.1 % aqueous tri-
fluoroacetic acid (TFA) and B =MeCN). For metabolism
studies, HPLC analysis was performed using system 2: A
Waters Chromatograph (Waters, Vienna, Austria) with a
600E multisolvent delivery system coupled to a Gabi
gamma detector (Raytest, Germany) employing a 0.5-mL
injection loop was applied. Data processing and chroma-
tography run were controlled with Empower Software,
and a Symmetry Shield RP-18 (5 μm, 3.9 mm× 20 mm)
column (Waters, Germany) was eluted adopting linear
gradient starting from 0 % B and advancing to 40 % B
within 40 min (solvent A = 0.1 % aqueous TFA and B =
MeCN) with a flow rate of 1 mL/min. Radioactivity mea-
surements were conducted in an automated well-type
gamma counter (NaI(Tl) crystal, Canberra Packard Auto-
Gamma 5000 series instrument) calibrated for 111In.
Biology
Cell lines and cell culture
The rat pancreatic tumor cell line AR42J, endogenously
expressing the CCK2R [27], was kindly provided by Prof.
C. Decristoforo (University Clinic Innsbruck, Austria).
The human epidermoid carcinoma A431 cell line trans-
fected to stably express the CCK2R (A431-CCK2R(+)) or
devoid of CCK2R expression (A431-CCK2R(−)) was a gift
from Prof. O. Boerman (Department of Nuclear Medicine,
Radboud University Nijmegen Medical Centre, Nijmegen,
The Netherlands) and Prof. L. Aloj (Istituto di Biostrutture
e Bioimmagini, Consiglio Nazionale delle Ricerche,
Naples, Italy) [28].
All culture media were purchased from Gibco BRL,
Life Technologies (Grand Island, NY, USA), and supple-
ments were supplied by Biochrom KG Seromed (Berlin,
Germany). AR42J cells were cultured in F-12K Nutrient
Mixture (Kaighn’s Modification), supplemented with
10 % (v/v) fetal bovine serum, 100 U/mL penicillin,
100 μg/mL streptomycin, and 1 mM L glutamine. A431-
CCK2R(+/−) cells were grown in Dulbecco’s Modified
Eagle medium with GlutaMAX-I supplemented with
10 % (v/v) fetal bovine serum, 100 U/mL penicillin,
100 μg/mL streptomycin, 4500 mg/L D-glucose, and
250 μg/mL G418. Cells were kept in a controlled hu-
midified air containing 5 % CO2 at 37 °C. Splitting of
cells with a ratio of 1:2 to 1:5 was performed when
approaching confluency using a trypsin/EDTA solution
(0.05/0.02 % w/v) [29].
Metabolism in blood
Animal experiments were carried out in compliance
with European and national regulations and were
approved by national authorities. For metabolic studies,
in-house male Swiss albino mice (30 ± 5 g) were used. A
bolus containing [111In-DOTA]MG11 (100 μL, 11–
22 MBq, 3 nmol of total peptide, normal saline/EtOH 9/
1 v/v) was injected in the tail vein of mice, together with
(a) vehicle (100 μL; control), (b) PA (100 μL of vehicle
containing 300 μg PA; PA), or (c) (100 μL of vehicle
containing 150 μg TO; TO). Additional animals intra-
peritoneally (ip) received a fine dispersed suspension of
Race (3 mg Race dissolved in 0.025 mL DMSO and freshly
mixed with 0.375 mL saline) 30–40 min prior to radioli-
gand injection. The animals were kept for 5 min in cages
with free access to water. They were sacrificed by cardiac
puncture under ether anesthesia, and blood was with-
drawn with a syringe and immediately placed in a pre-
chilled polypropylene vial on ice containing EDTA and
Met. Blood samples were centrifuged at 2000g at 4 °C for
10 min. The plasma was collected, an equal volume of
MeCN was added, and the mixture was centrifuged for
10 min at 15,000g at 4 °C. The supernatant was collected
and concentrated under a gentle N2-flux at 40 °C to a vol-
ume of ≈0.1 mL; the concentrate was diluted with physio-
logical saline (0.4 mL) and passed through a Millex-GV
syringe-driven filter unit (0.22 μm/13 mm; Millipore, Mil-
ford, USA). Suitable aliquots of the filtrate were analyzed
by RP-HPLC [15, 29]. The tR of the parent radiopeptide in
the applied chromatographic conditions (system 2) was
established by coinjection of samples with [111In-
DOTA]MG11.
Biodistribution in AR42J tumor-bearing SCID mice
In-house male SCID mice (NCSR “Demokritos” Animal
House) of 6 weeks of age at the time of arrival (18 ± 2 g
body weight) were inoculated subcutaneously (sc) in
their flanks with a suspension of freshly harvested
AR42J cells (1 × 107 cells in ~150 μL saline). Animals
were kept in aseptic conditions for 14 days when
well-palpable tumors developed at the inoculation
sites (0.31 ± 0.17 g) [29]. At the day of biodistribution,
animals received a bolus of [111In-DOTA]MG11
(100 μL, 37–74 kBq, 10 pmol total peptide, in saline/
EtOH 9/1 v/v) through the tail vein, coinjected with
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(a) vehicle (100 μL; control group, n = 10), (b) PA
(100 μL of vehicle containing 300 μg PA; PA group,
n = 10), (c) TO (100 μL of vehicle containing 150 μg
TO; TO group, n = 4), (d) Lis (100 μL of vehicle con-
taining 100 μg Lis; Lis group, n = 4), (e) PA plus Lis
(100 μL vehicle containing 300 μg PA and 100 μg Lis;
PA+Lis group, n = 5), or (f ) 30–40 min after ip injec-
tion of Race (3 mg Race dissolved in 0.025 mL
DMSO and freshly mixed with 0.375 mL saline; Race
group, n = 4). In a separate animal group, the mice
were coinjected with 100 μL vehicle containing both
300 μg PA and 100 μg DG2 [25] to assess non-
specific tumor uptake during in situ NEP inhibition
(in vivo CCK2R blockade; block group, n = 4).
Mice had access to drinking water ad libitum until
they were euthanized at 4 h pi. Blood samples, organs
of interest, and tumors were collected immediately
after dissection, weighted, and measured for radio-
activity in the gamma counter; only stomachs were
emptied of their contents prior to measurements.
Biodistribution data were calculated as percent of
injected dose per gram tissue (% ID/g) with the aid of
suitable standards of the injected dose, using the
GraphPad Prism Software (San Diego, CA).
PA and TO dose dependence study in SCID mice bearing
twin A431-CCK2R(+/−) tumors
Inocula of freshly harvested A431-CCK2R(+/−) cells
(1.6 × 107/1.4 × 107 cell suspensions in 150 μL saline)
were sc-injected in the right and left flanks of the
SCID mice (male SCID mice, 6 weeks of age and of
18 ± 2 g body weight on arrival day; NCSR “Demokri-
tos” Animal House). The animals were kept in asep-
tic conditions for 8 days till well-palpable tumors
(0.26 ± 0.08 g) developed at the inoculation sites [29].
At the day of the experiment, the mice received a
bolus of [111In-DOTA]MG11 (100 μL, 37–74 kBq,
10 pmol total peptide, in saline/EtOH 9/1 v/v)
through the tail vein, coinjected with (a) vehicle
(100 μL; control group, n = 5), (b) three different doses of
PA (3 μg, n = 5; 30 μg, n = 4; or 300 μg PA, n = 10,
dissolved in 100 μL vehicle), and (c) three different doses
of TO (1.5, 15, or 150 μg TO dissolved in 100 μL vehicle,
all groups of n = 4). Mice had free access to drinking water
until they were sacrificed at 4 h pi, and biodistribution was
conducted as described above.
Statistical analysis
The in vivo data were statistically analyzed with the
Student’s t test (Prism™ 2.01, GraphPad Software, San
Diego, CA). Analyses were two-tailed and a P value <0.05
was considered statistically significant.
Results
Radiolabeling
The radiolabeling of DOTA-MG11 with 111In was
straightforward following published methods and involved
20-min incubation of the peptide conjugate in acidic
medium at 90 °C in the presence of 111InCl3 [26]. A >96 %
radiometal incorporation was typically demonstrated by
RP-HPLC analysis (system 1). The radiochemical purity
was >97 %, verifying that the addition of Met in the label-
ing reaction mixture prevented the oxidation of Met15 in
the peptide chain (Additional file 1: Figure S1).
Metabolism in blood
As shown by HPLC analysis of mouse blood collected
5 min pi, [111In-DOTA]MG11 was very rapidly degraded
in vivo in agreement with previous findings (Fig. 2a) [8,
15, 26]. Treatment of mice with PA, TO, and its ip pre-
administered prodrug Race notably increased the
amount of intact radiotracer in peripheral blood from <5
to >70 % (Fig. 2b, c, d, respectively). Conversely, coinjec-
tion of [111In-DOTA] MG11 with the ACE inhibitor Lis
produced no change on radiotracer stability in mouse
circulation up to 5 min pi (results not shown), in sup-
port of the assumption that [111In-DOTA]MG11 is re-
sistant to ACE [18].
Biodistribution in AR42J tumor-bearing mice—impact of
NEP/ACE inhibitors
Results of [111In-DOTA]MG11 biodistribution in
SCID mice bearing AR42J tumors at 4 h pi are sum-
marized in Table 1 and in Fig. 3, as % ID/g (n ≥ 4). In
addition to the values obtained by coinjection of the
radiotracer with vehicle (controls), Table 1 includes
values obtained during treatment of mice with one of
the NEP inhibitors (PA, TO, and Race) and/or the
ACE inhibitor Lis. In all cases, the radiotracer rapidly
cleared from background tissues via the kidneys and
the urinary tract with consistently low renal values.
Uptake in the AR42J tumors remarkably increased
from 1.82 ± 1.25 %ID/g in controls to 15.32 ± 4.71 %
ID/g in the PA group (P < 0.001). Most importantly,
this increase was shown to be receptor specific, as
suggested by the significantly reduced tumor values
determined during coinjection of excess DG2 [25]
and PA (0.34 ± 0.04 % ID/g, P < 0.001). In contrast,
coinjection of the ACE inhibitor Lis did not provoke
any raise in tumor values (1.80 ± 0.74 % ID/g) vs.
controls (P > 0.05), whereas coinjection of both
peptidase inhibitors PA and Lis did not provoke any
additional increase in the PA group values (14.51 ±
4.73 % ID/g, P > 0.05). This finding is a strong indica-
tion that ACE is not involved in the in vivo catabol-
ism of [111In-DOTA]MG11.
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On the other hand, coinjection of TO, at a dose equi-
molar to PA, produced similar albeit slightly less potent
increase of AR42J tumor uptake (12.32 ± 3.66 % ID/g,
P > 0.05). Interestingly, the TO prodrug Race although
administered at a ten times higher dose than TO induced
half as high an increase in the tumor uptake of
[111In-DOTA]MG11 (6.81 ± 2.79 %ID/g, P < 0.001).
Biodistribution in A431-CCK2R(+/−) tumor-bearing
mice—impact of PA and TO dose
The efficacy of the two NEP inhibitors PA and TO in
improving the in vivo targeting of [111In-DOTA]MG11
was compared at 4 h pi in SCID mice bearing double
A431-CCK2R(+/−) tumors. Three gradually increasing
inhibitor doses and equimolar for PA (3, 30, and 300 μg)
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Fig. 2 Stability of [111In-DOTA]MG11 in peripheral mouse blood at 5 min pi. Analysis by HPLC (system 2) of murine blood collected 5 min after
injection of [111In-DOTA] MG11 with a vehicle (<4 % intact radiotracer), b PA (300 μg; >70 % intact radiopeptide), c TO (150 μg; >70 % intact
radiopeptide), or d 30–40 min after ip injection of Race (2 mg; >70 % intact radiopeptide). The tR of [
111In-DOTA]MG11 is indicated by the arrow
Table 1 Cumulative biodistribution data of [111In-DOTA]MG11 in AR42J tumor-bearing SCID mice including controls and animals
treated with NEP and/or ACE inhibitors
Organs [111In-DOTA]MG11 (%ID/g tissue ± SD at 4 h pi, n ≥ 4)
+DG2 + PAa Control +Lisb +PAc +PA + Lisd +TOe +Racef
Blood 0.02 ± 0.01 0.04 ± 0.01 0.05 ± 0.02 0.06 ± 0.04 0.05 ± 0.02 0.02 ± 0.01 0.20 ± 0.08
Liver 0.14 ± 0.02 0.13 ± 0.03 0.13 ± 0.01 0.15 ± 0.04 0.17 ± 0.09 0.17 ± 0.05 1.19 ± 0.03
Heart 0.02 ± 0.01 0.05 ± 0.02 0.05 ± 0.01 0.07 ± 0.03 0.07 ± 0.03 0.03 ± 0.02 0.13 ± 0.03
Kidneys 1.31 ± 0.03 1.86 ± 0.25 1.85 ± 0.30 2.26 ± 0.33 1.82 ± 0.06 2.95 ± 0.80 1.93 ± 0.46
Stomach 0.08 ± 0.01 1.53 ± 0.65 2.83 ± 0.68 5.13 ± 2.29 6.21 ± 2.73 2.90 ± 0.51 4.60 ± 1.09
Intestines 0.48 ± 0.08 0.89 ± 0.76 0.65 ± 0.25 0.69 ± 0.13 0.82 ± 0.26 2.16 ± 0.88 0.83 ± 0.12
Spleen 0.09 ± 0.02 0.17 ± 0.07 0.34 ± 0.30 0.20 ± 0.08 0.30 ± 0.13 0.14 ± 0.04 0.30 ± 0.06
Muscle 0.01 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.09 ± 0.17 0.07 ± 0.04 0.02 ± 0.01 0.10 ± 0.03
Lung 0.05 ± 0.01 0.07 ± 0.02 0.07 ± 0.01 0.10 ± 0.01 0.28 ± 0.19 0.12 ± 0.05 0.12 ± 0.03
Femur 0.04 ± 0.01 0.09 ± 0.05 0.08 ± 0.01 0.12 ± 0.06 0.15 ± 0.04 0.05 ± 0.01 0.26 ± 0.22
Pancreas 0.08 ± 0.01 0.11 ± 0.03 0.18 ± 0.09 0.36 ± 0.17 0.53 ± 0.24 0.30 ± 0.16 0.30 ± 0.061
Tumor 0.34 ± 0.04 1.82 ± 1.25 1.80 ± 0.74 15.32 ± 4.71 14.51 ± 4.73 12.32 ± 3.66 6.81 ± 2.79
aCoinjection of 50 nmol DG2 [25] and 300 μg PA to assess non-specific tumor uptake
bCoinjection of 100 μg Lis
cCoinjection with 300 μg PA
dCoinjection with 300 μg PA and 100 μg Lis
eCoinjection with 150 μg TO
fRadiotracer injection 30–40 min after ip injection of 3 mg Race
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and TO (1.5, 15, and 150 μg) were tested, and the
respective results are summarized in Table 2 and
Fig. 4. It is interesting to note that in all cases, a
significant and receptor-specific increase was re-
corded in the uptake of the radiotracer in the
CCK2R-expressing tumors (P < 0.001), whereas no
change was observed in the tumors devoid of CCK2R
expression. Stepwise increase of TO dose resulted in
significant and gradual increase of tumor uptake vs.
controls. In the case of PA, however, increasing the dose
from 30 to 300 μg did not further improve tumor uptake.
Overall, PA clearly exerted a more potent tumor enhance-
ment effect compared to the respective equimolar doses
of TO (P < 0.001).
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Fig. 3 a Uptake of [111In-DOTA]MG11 in kidneys and AR42J tumors at 4 h pi in SCID mice. Data are given for kidneys and tumors as mean of
%ID/g ± SD, n ≥ 4; [111In-DOTA]MG11 iv-coinjection with vehicle ( ), with 100 μg Lis ( ), with 300 μg PA ( ), with a mixture of 100 μg Lis and
300 μg PA ( ), with 150 μg TO ( ), or 30–40 min after ip injection of 3 mg Race ( ); for CCK2R blockade, 40 nmol DG2 [25] was iv-coinjected along
with 300 μg PA ( ). b Corresponding tumor-to-kidney ratios (Tu/Ki)
Table 2 Comparative biodistribution data of [111In-DOTA]MG11 in SCID mice bearing double A431-CCK2R(+/−) tumors at 4 h pi,
including controls and animals coinjected with gradually increasing amounts of TO and PA; TO and PA injected doses were equimolar
Organs [111In-DOTA]MG11 (%ID/g tissue ± SD at 4 h pi, n ≥ 4)
Control +TO +PA
1.5 μg 15 μg 150 μg 3 μg 30 μg 300 μg
Blood 0.01 ± 0.01 0.02 ± 0.01 0.03 ± 0.02 0.02 ± 0.01 0.02 ± 0.01 0.04 ± 0.01 0.02 ± 0.01
Liver 0.11 ± 0.02 0.16 ± 0.02 0.15 ± 0.02 0.16 ± 0.01 0.13 ± 0.03 0.13 ± 0.02 0.12 ± 0.01
Heart 0.02 ± 0.01 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.01 0.02 ± 0.01 0.04 ± 0.01 0.03 ± 0.01
Kidneys 1.30 ± 0.29 2.67 ± 0.30 2.28 ± 0.21 2.22 ± 0.19 2.11 ± 0.45 2.81 ± 1.03 1.78 ± 0.37
Stomach 1.32 ± 0.26 2.59 ± 0.40 3.38 ± 0.20 4.01 ± 0.20 2.68 ± 0.67 3.19 ± 0.12 4.56 ± 1.16
Intestines 0.83 ± 0.53 0.43 ± 0.10 0.47 ± 0.04 0.48 ± 0.02 0.40 ± 0.17 0.32 ± 0.09 0.47 ± 0.20
Spleen 0.06 ± 0.01 0.12 ± 0.02 0.10 ± 0.01 0.14 ± 0.04 0.09 ± 0.04 0.10 ± 0.02 0.07 ± 0.01
Muscle 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.02 0.03 ± 0.01 0.04 ± 0.01 0.02 ± 0.01
Lung 0.03 ± 0.01 0.05 ± 0.00 0.05 ± 0.00 0.62 ± 0.02 0.07 ± 0.05 0.07 ± 0.01 0.07 ± 0.03
Femur 0.02 ± 0.01 0.05 ± 0.00 0.06 ± 0.00 0.09 ± 0.07 0.04 ± 0.03 0.05 ± 0.01 0.06 ± 0.01
Pancreas 0.05 ± 0.02 0.14 ± 0.03 0.12 ± 0.03 0.22 ± 0.04 0.14 ± 0.07 0.17 ± 0.02 0.20 ± 0.03
Tumor (−) 0.12 ± 0.02 0.18 ± 0.03 0.13 ± 0.01 0.17 ± 0.04 0.17 ± 0.0.13 0.18 ± 0.07 0.13 ± 0.02
Tumor (+) 2.50 ± 0.92 4.98 ± 0.58 6.10 ± 1.26 7.99 ± 1.12 10.55 ± 1.77 15.41 ± 2.28 16.05 ± 2.37
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Discussion
The advent of radiolabeled somatostatin analogs, like
OctreoScan® ([111In-DTPA]octreotide) and Lutathera®
([177Lu-DOTA]Tate), in the management of sst2-express-
ing neuroendocrine tumors [30], has established the ap-
plication of peptide radioligands for molecular imaging
and radionuclide therapy of tumors. This success has
largely depended on the metabolic robustness of the
cyclic-octapeptide analogs applied. The evolution of
peptide receptor-targeted diagnosis and therapy beyond
the boundaries of sst2-positive neuroendocrine tumors is
valid based on the overexpression of other peptide
receptors in a variety of human tumors [31]. However,
progress in this direction has been greatly restricted by
the sub-optimal metabolic stability of peptide radioli-
gands. Structural interventions to improve metabolic
stability often deteriorate other important biological fea-
tures of radiopeptides, as for example receptor affinity
or pharmacokinetics [9].
We have recently proposed the in situ stabilization of
biodegradable radiopeptides by coinjection of a suitable
protease inhibitor, leading to significant improvement of
tumor uptake [15]. This concept has indeed led to im-
pressive diagnostic signal amplification on tumor lesions
in preclinical models and was recently shown to improve
the outcome of radionuclide therapy as well [32]. Espe-
cially in the case of [111In-DOTA]MG11 and other radi-
olabeled gastrins, high enhancement of tumor uptake
combined with a preserved low kidney retention were
observed, resulting in particularly appealing tumor-to-
kidney ratios [18, 29]. These preclinical results, obtained
after coinjection of [111In-DOTA]MG11 with the NEP
inhibitor PA, warrant further validation in a “proof-of-
principle” study in patients.
It should be noted, that our studies on in situ radio-
peptide stabilization and enhancement of tumor uptake
have primarily been focused on NEP inhibition by PA.
Remarkably, a great variety of radioligands originating
from different peptide families, including somatostatin,
bombesin, and gastrin, have profited by application of
this simple methodology, revealing a central role of NEP
in initiating the in vivo degradation of these analogs
[15]. The impact of in situ NEP inhibition relies on the
abundant and ubiquitous presence of this ectoenzyme in
the body combined with its broad substrate specificity
[14]. However, NEP may not always exclusively deter-
mine the in vivo fate of radiopeptides. For example, ACE
has often been implicated in the degradation of peptide
ligands, and its role in the in vitro degradation of
different-length gastrin analogs has been previously
reported [10]. It should be stressed that the impact of in
situ ACE inhibition on the bioavailability and tumor
localization of [111In-DOTA]MG11 in vivo has not been
thus far investigated.
For this purpose, in our study we have coinjected
[111In-DOTA]MG11 together with the potent ACE in-
hibitor Lis, a registered antihypertensive drug [19]. As a
result, we were not able to observe any change in the
radioligand uptake in AR42J tumors in mice treated with
Lis vs. controls at 4 h pi. In addition, dual NEP/ACE
inhibition by combined coinjection of both Lis and PA
inhibitors with [111In-DOTA]MG11 induced no additive
a b
0
2
4
6
8
10
12
14
16
18
20
%
 ID
/g
0
1
2
3
4
5
6
7
8
9
10
11
12
Ki Tu - Tu + Tu/Ki
Fig. 4 a Uptake of [111In-DOTA]MG11 in kidneys and A431-CCK2R(+) and A431-CCK2R(−) tumors at 4 h pi in SCID mice for controls and increasing
amounts of the NEP inhibitors TO and PA. Data are given as mean of %ID/g ± SD, n≥ 4. [111In-DOTA]MG11 iv-coinjection with vehicle ( ), with
1.5 μg TO ( ), with 15 μg TO ( ), with 150 μg TO ( ), with 3 μg PA ( ), with 30 μg PA ( ), or 300 μg PA ( ) in SCID mice bearing twin
A431-CCK2R(+) (Tu+) and naïve A431-CCK2R(−) (Tu−) human xenografts. b Corresponding tumor-to-kidney ratios (Tu/Ki)
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effect vs. single NEP inhibition by PA (Table 1, Fig. 3;
P > 0.05). These findings strongly suggest that ACE does
not contribute to the in vivo processing of [111In-
DOTA]MG11 and verify NEP as the major degrading
protease.
Owing to the fast kinetics of radiopeptide localization to
target sites upon entry in the bloodstream, only rapidly oc-
curring degradation events—as those related to NEP—are
relevant for tumor-targeting efficacy. Hence, the onset of
NEP inhibition should occur and reach its maximum quite
rapidly but not last longer than the time needed for the
radioactivity to clear from blood and access the target. In
this respect, the inhibitor should preferably induce rapid,
complete, and transient NEP inhibition. In addition, it
should be potent, water-soluble, chemically stable, and
available at a reasonable cost. PA combines most of the
above desirable properties; however, it has not been
thoroughly investigated in terms of biosafety [17]. Only
very low amounts of PA have been administered in human,
not sufficient for in vivo effective inhibition of NEP [20].
Aiming at clinical translation, our interest has been
attracted by two clinically certified NEP inhibitors, TO
and its prodrug Race. TO is a potent, reversible NEP
inhibitor with a relative rapid onset of action [21], but
its water solubility is not ideal for iv injection as a bolus
together with the radiopeptide. It has been previously
tested in high doses in human, as for example by iv infu-
sion of 150 mg in 250 mL of isotonic glucose in 42
patients showing excellent hemodynamic tolerance [22].
The impact of TO on the bioavailability and tumor up-
take of our paradigm compound [111In-DOTA]MG11
was compared vs. PA 4 h after coinjection of the radio-
tracer with equimolar amounts of either inhibitor in
AR42J tumor-bearing mice. As a result, we observed
comparable and impressive enhancement of tumor
values (Table 1, Fig. 3). On the other hand, Race is a reg-
istered antidiarrheal drug for oral use and a prodrug for
TO [23, 24]. Due to its poor water solubility, it cannot
be iv-administered in mice and was instead ip-
injected in high molar excess (10-fold than the TO
dose) 30–40 min prior to the iv injection of [111In-
DOTA]MG11. As a result, tumor values significantly
increased compared to controls but half as efficiently
compared to the iv-injected hydrophilic inhibitors PA
and TO. This finding highlights the significance of
administration route and actual concentration of the
inhibitor in the blood at the time of the radiotracer
injection to achieve maximum enhancement of uptake
on tumor lesions.
In the last part of this study, the efficacy of TO to en-
hance the uptake of [111In-DOTA]MG11 specifically in
human CCK2R(+)-expressing tumors was compared vs.
PA at progressively increasing administered doses in
mice bearing double A431-CCK2R(+/−) tumors (Table 2,
Fig. 4). While both NEP inhibitors induced significant
and CCK2R-specific tumor uptake enhancement even at
the lowest administered doses (1.5 μg TO and 3 μg PA),
PA showed consistently superior efficacy at all tested
dose levels compared to TO (P < 0.001). Remarkably, PA
reached maximum tumor uptake enhancement at the
30 μg dose already, whereas TO reached half as high
tumor values at the corresponding 10-fold molar dose of
150 μg. These intriguing findings may be tentatively
assigned to the free thiol functionality of TO (Fig. 1).
This strong nucleophile is prone to interact in vivo with
electrophiles, and hence, the effective dose of TO might
be much lower than originally anticipated. In fact,
previous reports have demonstrated the fast in vivo
inactivation of thiol-based NEP inhibitors, including
TO [33, 34]. Another practical disadvantage of thiols
is their propensity to oxidize in aqueous solutions to
the respective disulfides, and hence, their storage for
longer time periods in ready to use formulations for
clinical application becomes challenging.
Conclusions
In summary, translation of the concept of in situ
stabilization of biodegradable peptide radioligands to im-
prove tumor targeting and hence diagnostic sensitivity
and therapeutic efficacy, from the preclinical setting into
patients, poses certain challenges that need to be compe-
tently addressed. Promising data thus far obtained from
mouse models for our paradigm radiotracer [111In-
DOTA]MG11 and the NEP inhibitor PA have been dir-
ectly compared herein with results retrieved after treat-
ment of mice with the ACE inhibitor Lis and the NEP
inhibitors TO and Race, all of which have been clinically
tested previously. This study has shown that only NEP in-
hibition is relevant for clinical translation. It has also
shown that significant enhancement of the radiotracer
tumor uptake is indeed feasible by both TO and Race.
However, for maximum efficacy, matching that of PA, fur-
ther studies need to be performed to optimize dose, ad-
ministration route, and time of inhibitor injection in
respect to radiotracer injection and are currently actively
pursued.
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